Can psychedelic compounds play a part in drug dependence therapy?
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Self-citationMesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders
Miller, W. R., & Wilbourne, P. L. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00019.x · Cited by 805
A systematic review of rapid diagnostic tests for the detection of tuberculosis infection
Dinnes, J., Deeks, J., Kunst, H., Gibson, A., Cummins, E., Waugh, N., Drobniewski, F., & Lalvani, A. (2007) · Health Technology Assessment · doi:10.3310/hta11030 · Cited by 666
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Cited by
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
“Data important in understanding the safety, mechanisms of action, and potential future indications for psilocybin-assisted treatment have included the treatment of substance use disorders (Bogenschutz et al., 2015; Garcia-Romeu et al., 2014; Johnson et al., 2012, 2014, 2017; Johnson and Griffiths, 2017; Nichols et al.…”
Self-citationPsychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
Self-citationCessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Self-citationSoler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4377-8 · Cited by 201
“In the past decade, a renewed interest in the therapeutic potential of psychedelics has emerged (Anderson 2012; McKenna 2004; Sessa and Johnson 2015).”
Background
Metadata
- Authors
- Sessa, B., & Johnson, M. W.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2015-01
- Volume
- 206
- Issue
- 1
- Pages
- 1-3
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2020765068
- Cited by
- 57
- References
- 5
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can psychedelic compounds play a part in drug dependence therapy? https://app.cochat.ai/papers/10.1192/bjp.bp.114.148031
- The paper
- Sessa, B., & Johnson, M. W. (2015). Can psychedelic compounds play a part in drug dependence therapy? British Journal of Psychiatry. https://doi.org/10.1192/bjp.bp.114.148031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.